Literature DB >> 15660015

Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services.

Dawn K Smith1, Lisa A Grohskopf, Roberta J Black, Judith D Auerbach, Fulvia Veronese, Kimberly A Struble, Laura Cheever, Michael Johnson, Lynn A Paxton, Ida M Onorato, Alan E Greenberg.   

Abstract

The most effective means of preventing human immunodeficiency virus (HIV) infection is preventing exposure. The provision of antiretroviral drugs to prevent HIV infection after unanticipated sexual or injection-drug--use exposure might be beneficial. The U.S. Department of Health and Human Services (DHHS) Working Group on Nonoccupational Postexposure Prophylaxis (nPEP) made the following recommendations for the United States. For persons seeking care < or =72 hours after nonoccupational exposure to blood, genital secretions, or other potentially infectious body fluids of a person known to be HIV infected, when that exposure represents a substantial risk for transmission, a 28-day course of highly active antiretroviral therapy (HAART) is recommended. Antiretroviral medications should be initiated as soon as possible after exposure. For persons seeking care < or =72 hours after nonoccupational exposure to blood, genital secretions, or other potentially infectious body fluids of a person of unknown HIV status, when such exposure would represent a substantial risk for transmission if the source were HIV infected, no recommendations are made for the use of nPEP. Clinicians should evaluate risks and benefits of nPEP on a case-by-case basis. For persons with exposure histories that represent no substantial risk for HIV transmission or who seek care >72 hours after exposure, DHHS does not recommend the use of nPEP. Clinicians might consider prescribing nPEP for exposures conferring a serious risk for transmission, even if the person seeks care >72 hours after exposure if, in their judgment, the diminished potential benefit of nPEP outweighs the risks for transmission and adverse events. For all exposures, other health risks resulting from the exposure should be considered and prophylaxis administered when indicated. Risk-reduction counseling and indicated intervention services should be provided to reduce the risk for recurrent exposures.

Entities:  

Mesh:

Year:  2005        PMID: 15660015

Source DB:  PubMed          Journal:  MMWR Recomm Rep        ISSN: 1057-5987


  127 in total

1.  Subsequent HIV infection among men who have sex with men who used non-occupational post-exposure prophylaxis at a Boston community health center: 1997-2013.

Authors:  Sachin Jain; Catherine E Oldenburg; Matthew J Mimiaga; Kenneth H Mayer
Journal:  AIDS Patient Care STDS       Date:  2015-01       Impact factor: 5.078

2.  Sexual risk behaviors and acceptability of HIV pre-exposure prophylaxis among HIV-negative gay and bisexual men in serodiscordant relationships: a mixed methods study.

Authors:  Ronald A Brooks; Raphael J Landovitz; Rachel L Kaplan; Eli Lieber; Sung-Jae Lee; Thomas W Barkley
Journal:  AIDS Patient Care STDS       Date:  2011-12-07       Impact factor: 5.078

Review 3.  Antiretroviral medication for preventing HIV infection in nonoccupational settings.

Authors:  Isaac I Bogoch; Eileen P Scully; Kimon C Zachary
Journal:  CMAJ       Date:  2012-05-28       Impact factor: 8.262

4.  Antiretroviral therapy for adults infected with HIV: Guidelines for health care professionals from the Quebec HIV care committee.

Authors:  Danielle Rouleau; Claude Fortin; Benoît Trottier; Richard Lalonde; Normand Lapointe; Pierre Côté; Jean-Pierre Routy; Marie-France Matte; Irina Tsarevsky; Jean-Guy Baril
Journal:  Can J Infect Dis Med Microbiol       Date:  2011       Impact factor: 2.471

5.  Antiretroviral therapy as HIV prevention: status and prospects.

Authors:  Kenneth H Mayer; Kartik K Venkatesh
Journal:  Am J Public Health       Date:  2010-08-19       Impact factor: 9.308

6.  Trends in the use of oral emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infection, United States, 2012-2017.

Authors:  Patrick S Sullivan; Robertino Mera Giler; Farah Mouhanna; Elizabeth S Pembleton; Jodie L Guest; Jeb Jones; Amanda D Castel; Howa Yeung; Michael Kramer; Scott McCallister; Aaron J Siegler
Journal:  Ann Epidemiol       Date:  2018-06-22       Impact factor: 3.797

7.  Deep transcriptional sequencing of mucosal challenge compartment from rhesus macaques acutely infected with simian immunodeficiency virus implicates loss of cell adhesion preceding immune activation.

Authors:  Fredrik Barrenas; Robert E Palermo; Brian Agricola; Michael B Agy; Lauri Aicher; Victoria Carter; Leon Flanary; Richard R Green; Randy McLain; Qingsheng Li; Wuxun Lu; Robert Murnane; Xinxia Peng; Matthew J Thomas; Jeffrey M Weiss; David M Anderson; Michael G Katze
Journal:  J Virol       Date:  2014-05-07       Impact factor: 5.103

8.  Discounting of Condom-Protected Sex as a Measure of High Risk for Sexually Transmitted Infection Among College Students.

Authors:  Anahí Collado; Patrick S Johnson; Jennifer M Loya; Matthew W Johnson; Richard Yi
Journal:  Arch Sex Behav       Date:  2016-10-03

9.  Post-exposure prophylaxis use and recurrent exposure to HIV among men who have sex with men who use crystal methamphetamine.

Authors:  Catherine E Oldenburg; Sachin Jain; Kenneth H Mayer; Matthew J Mimiaga
Journal:  Drug Alcohol Depend       Date:  2014-11-26       Impact factor: 4.492

Review 10.  Preparing for HIV pre-exposure prophylaxis: lessons learned from post-exposure prophylaxis.

Authors:  Stephanie E Cohen; Albert Y Liu; Kyle T Bernstein; Susan Philip
Journal:  Am J Prev Med       Date:  2013-01       Impact factor: 5.043

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.